Diabetic patients are one step closer to avoiding related heart, kidney and eye complications, thanks to the combined efforts of researchers at the Joslin Diabetes Center and the Eli Lilly Pharmaceutical Company.
Dr. George L. King, professor of medicine at Harvard Medical School (HMS) and the Joslin Diabetes Center, has devoted more than 10 years of research to studying the effects of protein kinase C (PKC), a vital enzyme that regulates cells in the vascular system, on vascular complications in diabetics.
One of 12 known forms of PKC has been found to be "preferentially activated by diabetes and high glucose levels," King says, "[and] a high glucose level is thought to be the main cause of blood vessel problems in the heart, kidney and eye in diabetic patients."
A few years ago, King began to design an inhibitor to prevent this form of PKC from constricting blood flow and causing vessel leakage in the retina of the eye.
Along with fellow researchers Dr. Lloyd P. Aiello, assistant professor of ophthalmology at HMS and the Joslin Diabetes Center, and Dr. Szen Bursell, assistant professor of ophthalmology at HMS, the inhibitor, now known as LY333531, was created.
When tested on diabetic animals, the researchers found the inhibitor to be effective and non-toxic. These results were successful enough to warrant an initial ophthalmologic clinical trial, the results of which were first announced at last month's symposium honoring the 100th birthday of the Joslin Diabetes Center.
In its initial clinical trial, LY333531 helped the blood flowing through the retinas of diabetic patients remain at equivalent levels to those without diabetes, without creating any notable side effects.
The initial trial consisted of 29 individuals with types I and II diabetes, who were administered the oral drug for a month. Future trials will be conducted on a larger scale and will continue to study the effects of the inhibitor on blindness. If the next study, which consists of a thousand patients, proves effective, King and Aiello say they will send their findings to the FDA for approval.
"But it all depends on the effectiveness shown," cautions King.
After more studies are conducted on the effects of LY333531 on diabetic blindness, researchers hope to investigate the inhibitors' effectiveness on diabetic cardiovascular malfunctions.
"We have produced quite a bit of animal data to show [that] it's helpful to heart and diabetic kidney [disease,]" King said. "Hopefully, trials will start soon."
Read more in News
Safran Sees Israeli Victory, Predicts Quick Egyptian FallRecommended Articles
-
Behind the Pro-Life PreachingC rack! That was the sound of the Christian Right punching my jaw as I walked out of my Adams
-
Diabates, Expert, HMS Professor Dies at 83Robert F. Bradley, a diabetes expert who brought awareness of the disease to the courtroom and the classroom, died on
-
Researchers Discover Potential Diabetes CureAs a college student in Australia, Maria Koulmanda began researching type 1 diabetes as part of a summer job. Thirty
-
The Med School’s Sweetest Professor Wins AwardA self-proclaimed “salesman of science,” C. Ronald Kahn says he loves simplifying the complexity of Type 2 Diabetes in order
-
Gene Linked to Heart Disease in DiabeticsA new study by a team of researchers at Harvard Medical School found a correlation between a genetic variant and
-
Harvard Researchers Find Potential Clue to Solving Type 1 DiabetesIn a recent study conducted by the Hotamisligil Laboratory at the Harvard School of Public Health, a group of scientists discovered that a naturally occurring molecule called TUDCA, or Tauroursodeoxycholic acid, could prevent Type 1 Diabetes.
